Patent US4752464A successfully refreshed from Google Patents.
US4752464A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Treatment of arthritis, including rheumatoid arthritis, with radioactive isotopes
Assignee: CADEMA MEDICAL PRODUCTS Inc 569 NORTH STREET MIDDLETOWN NEW YORK 10940 USA A CORP OF DE
•
Filing: 1985-06-07
•
Granted: 1988-06-21
•
Expires: 2005-06-07
Abstract
Abstract Treatment of rheumatoid arthritis by administering a radioactive compound to the inflamed synovium of the articular joint. The compound comprises an aggregate suspension having a radionuclide entrapped therein. The aggregate suspension is a ferric or aluminum hydroxide aggregate, and the radionuclide is selected from the group consisting of 166 Holmium, 153 Samarium, 175 Ytterbium, 169 Erbium, and 176m Lutetium. The radionculide may also consist of 51 Chromium. Suitable leakage inhibitors or agents to reduce leakage of the radionuclide from the articular joint is included as part of the chemical composition of the final drug form.
Inventors
- 👤 Ephraim Lieberman
- 👤 Maurice E. Bordoni
- 👤 Alfred K. Thornton
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 18:14
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/12; A61K51/1217; A61K51/1241; A61K51/1255; A61K2121/00
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
38 words
A radioactive composition for the treatment of arthritis comprising, in combination, a ferric hydroxide or aluminum hydroxide aggregate suspension having a particle size of 3 to 20 microns, wherein a radionuclide is entrapped, said radionuclide being 166 Holmium.
Claim 2
Dependent Claim
38 words
A radioactive composition for the treatment of arthritis comprising, in combination, a ferric hydroxide or aluminum hydroxide aggregate suspension having a particle size of 3 to 20 microns, wherein a radionuclide is entrapped, said radionuclide being 166 Holmium.
Claim 3
Dependent Claim
36 words
A method for the treatment of arthritis comprising administering an effective amount of the radioactive composition of claim 1 to the inflamed synovium of the particular joint of a mammal body in need of such treatment.
Claim 4
Dependent Claim
34 words
A radioactive composition consisting essentially of, in combination, a ferric hydroxide aggregate suspension having a particle size substantially in a range of 3-20 microns, wherein a radionuclide is entrapped, said radionuclide being 166 Holmium.
Claim 5
Dependent Claim
34 words
A radioactive composition consisting essentially of, in combination, a ferric hydroxide aggregate suspension having a particle size substantially in a range of 3-20 microns, wherein a radionuclide is entrapped, said radionuclide being 166 Holmium.
Claim 6
Dependent Claim
38 words
A radioactive composition for the treatment of rheumatoid arthritis comprising, in combination, a ferric hydroxide aggregate suspension having a particle size substantially in a range of 3-20 microns, wherein a radionuclide is entrapped, said radionuclide being 166 Holmium.
Claim 7
Dependent Claim
38 words
A radioactive composition for the treatment of rheumatoid arthritis comprising, in combination, a ferric hydroxide aggregate suspension having a particle size substantially in a range of 3-20 microns, wherein a radionuclide is entrapped, said radionuclide being 166 Holmium.
References Cited (Backward Citations)
US3961038A
Cited
EP0176288A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-06-21 | 1991-12-21 | 1992-06-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-06-21 | 1995-12-21 | 1996-06-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-06-21 | 1999-12-21 | 2000-06-21 | $7700.00 | Window Closed / Lapsed |